S&P 500   4,310.13 (+0.24%)
DOW   33,628.06 (-0.11%)
QQQ   360.11 (+0.59%)
AAPL   172.00 (+0.77%)
MSFT   317.56 (+1.25%)
META   305.65 (+0.56%)
GOOGL   132.05 (-0.20%)
AMZN   127.72 (+1.38%)
TSLA   252.16 (+2.35%)
NVDA   437.38 (+1.51%)
NIO   9.06 (+1.68%)
BABA   87.00 (+1.71%)
AMD   103.83 (+1.04%)
T   15.00 (-0.07%)
F   12.60 (+0.32%)
MU   68.02 (+4.33%)
CGC   0.81 (-0.42%)
GE   110.74 (-1.42%)
DIS   80.84 (+0.89%)
AMC   8.00 (+2.70%)
PFE   32.85 (+2.37%)
PYPL   58.69 (+0.88%)
NFLX   377.45 (+0.29%)
S&P 500   4,310.13 (+0.24%)
DOW   33,628.06 (-0.11%)
QQQ   360.11 (+0.59%)
AAPL   172.00 (+0.77%)
MSFT   317.56 (+1.25%)
META   305.65 (+0.56%)
GOOGL   132.05 (-0.20%)
AMZN   127.72 (+1.38%)
TSLA   252.16 (+2.35%)
NVDA   437.38 (+1.51%)
NIO   9.06 (+1.68%)
BABA   87.00 (+1.71%)
AMD   103.83 (+1.04%)
T   15.00 (-0.07%)
F   12.60 (+0.32%)
MU   68.02 (+4.33%)
CGC   0.81 (-0.42%)
GE   110.74 (-1.42%)
DIS   80.84 (+0.89%)
AMC   8.00 (+2.70%)
PFE   32.85 (+2.37%)
PYPL   58.69 (+0.88%)
NFLX   377.45 (+0.29%)
S&P 500   4,310.13 (+0.24%)
DOW   33,628.06 (-0.11%)
QQQ   360.11 (+0.59%)
AAPL   172.00 (+0.77%)
MSFT   317.56 (+1.25%)
META   305.65 (+0.56%)
GOOGL   132.05 (-0.20%)
AMZN   127.72 (+1.38%)
TSLA   252.16 (+2.35%)
NVDA   437.38 (+1.51%)
NIO   9.06 (+1.68%)
BABA   87.00 (+1.71%)
AMD   103.83 (+1.04%)
T   15.00 (-0.07%)
F   12.60 (+0.32%)
MU   68.02 (+4.33%)
CGC   0.81 (-0.42%)
GE   110.74 (-1.42%)
DIS   80.84 (+0.89%)
AMC   8.00 (+2.70%)
PFE   32.85 (+2.37%)
PYPL   58.69 (+0.88%)
NFLX   377.45 (+0.29%)
S&P 500   4,310.13 (+0.24%)
DOW   33,628.06 (-0.11%)
QQQ   360.11 (+0.59%)
AAPL   172.00 (+0.77%)
MSFT   317.56 (+1.25%)
META   305.65 (+0.56%)
GOOGL   132.05 (-0.20%)
AMZN   127.72 (+1.38%)
TSLA   252.16 (+2.35%)
NVDA   437.38 (+1.51%)
NIO   9.06 (+1.68%)
BABA   87.00 (+1.71%)
AMD   103.83 (+1.04%)
T   15.00 (-0.07%)
F   12.60 (+0.32%)
MU   68.02 (+4.33%)
CGC   0.81 (-0.42%)
GE   110.74 (-1.42%)
DIS   80.84 (+0.89%)
AMC   8.00 (+2.70%)
PFE   32.85 (+2.37%)
PYPL   58.69 (+0.88%)
NFLX   377.45 (+0.29%)
NASDAQ:HRMY

Harmony Biosciences (HRMY) Stock Forecast, Price & News

$33.15
-1.21 (-3.52%)
(As of 12:09 PM ET)
Compare
Today's Range
$33.10
$34.60
50-Day Range
$31.89
$39.03
52-Week Range
$29.81
$62.08
Volume
119,340 shs
Average Volume
675,605 shs
Market Capitalization
$1.99 billion
P/E Ratio
10.14
Dividend Yield
N/A
Price Target
$60.78

Harmony Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
76.9% Upside
$60.78 Price Target
Short Interest
Bearish
21.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.56mentions of Harmony Biosciences in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
33.75%
From $2.40 to $3.21 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.30 out of 5 stars

Medical Sector

7th out of 970 stocks

Pharmaceutical Preparations Industry

1st out of 456 stocks


HRMY stock logo

About Harmony Biosciences (NASDAQ:HRMY) Stock

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

HRMY Price History

HRMY Stock News Headlines

Uranium Prices Surge as Nuclear Energy Becomes Key
Renewed interest in uranium and rising prices have created a favorable environment for new projects.
Harmony Biosciences (NASDAQ:HRMY) Sees Strong Trading Volume
Uranium Prices Surge as Nuclear Energy Becomes Key
Renewed interest in uranium and rising prices have created a favorable environment for new projects.
Harmony Biosciences' (HRMY) Buy Rating Reaffirmed at Mizuho
9 Analysts Have This to Say About Harmony Biosciences
Will Harmony's INTUNE Trial Data Strike A Chord?
Expert Ratings for Harmony Biosciences
Harmony Biosciences To Acquire Zynerba Pharma For Up To $200 Mln
See More Headlines
Receive HRMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter.

HRMY Company Calendar

Last Earnings
8/01/2023
Today
9/29/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HRMY
Fax
N/A
Employees
200
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$60.78
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$43.00
Forecasted Upside/Downside
+76.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Net Income
$181.47 million
Pretax Margin
26.85%

Debt

Sales & Book Value

Annual Sales
$437.86 million
Cash Flow
$3.55 per share
Book Value
$6.79 per share

Miscellaneous

Free Float
42,960,000
Market Cap
$2.06 billion
Optionable
Not Optionable
Beta
0.43
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Jeffrey S. Aronin (Age 55)
    Founder & Non-Exec. Chairman
    Comp: $19.6k
  • Dr. Jeffrey M. Dayno M.D. (Age 66)
    Pres, CEO & Director
    Comp: $762.15k
  • Mr. Sandip S. Kapadia CPA (Age 53)
    M.B.A., Exec. VP & CFO
    Comp: $962.6k
  • Mr. Jeffrey Dierks M.B.A. (Age 51)
    Exec. VP & Chief Commercial Officer
    Comp: $662.1k
  • Mr. Andrew Serafin J.D. (Age 48)
    M.B.A., Exec. VP & Chief Strategy Officer
    Comp: $605.42k
  • Mr. David Bradshaw
    Head of Technical Operations
  • Luis Sanay
    Head of Investor Relations
  • Mr. Christian Ulrich
    Gen. Counsel & Corp. Sec.
  • Ms. Tricia Glover
    Chief Compliance Officer
  • Ms. Audrey Murphy
    Head of HR













HRMY Stock - Frequently Asked Questions

Should I buy or sell Harmony Biosciences stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harmony Biosciences in the last twelve months. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HRMY shares.
View HRMY analyst ratings
or view top-rated stocks.

What is Harmony Biosciences' stock price forecast for 2023?

10 Wall Street analysts have issued 1-year target prices for Harmony Biosciences' stock. Their HRMY share price forecasts range from $43.00 to $75.00. On average, they anticipate the company's share price to reach $60.78 in the next year. This suggests a possible upside of 76.9% from the stock's current price.
View analysts price targets for HRMY
or view top-rated stocks among Wall Street analysts.

How have HRMY shares performed in 2023?

Harmony Biosciences' stock was trading at $55.10 on January 1st, 2023. Since then, HRMY shares have decreased by 37.6% and is now trading at $34.36.
View the best growth stocks for 2023 here
.

Are investors shorting Harmony Biosciences?

Harmony Biosciences saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 7,350,000 shares, a decline of 5.0% from the August 31st total of 7,740,000 shares. Based on an average daily volume of 532,100 shares, the days-to-cover ratio is currently 13.8 days. Approximately 21.6% of the shares of the company are short sold.
View Harmony Biosciences' Short Interest
.

When is Harmony Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our HRMY earnings forecast
.

How were Harmony Biosciences' earnings last quarter?

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) announced its quarterly earnings results on Tuesday, August, 1st. The company reported $0.56 earnings per share for the quarter, missing the consensus estimate of $0.62 by $0.06. The company earned $134.22 million during the quarter, compared to analysts' expectations of $139.79 million. Harmony Biosciences had a net margin of 40.16% and a trailing twelve-month return on equity of 42.49%.

What other stocks do shareholders of Harmony Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harmony Biosciences investors own include Advance Auto Parts (AAP), Advanced Micro Devices (AMD), Boeing (BA), Berry Global Group (BERY), Bunge (BG), Carrier Global (CARR), Commercial Metals (CMC), Canadian Solar (CSIQ), Deere & Company (DE) and Eastman Chemical (EMN).

When did Harmony Biosciences IPO?

(HRMY) raised $101 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 4,700,000 shares at $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler served as the underwriters for the IPO.

What is Harmony Biosciences' stock symbol?

Harmony Biosciences trades on the NASDAQ under the ticker symbol "HRMY."

How do I buy shares of Harmony Biosciences?

Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harmony Biosciences' stock price today?

One share of HRMY stock can currently be purchased for approximately $34.36.

How much money does Harmony Biosciences make?

Harmony Biosciences (NASDAQ:HRMY) has a market capitalization of $2.06 billion and generates $437.86 million in revenue each year. The company earns $181.47 million in net income (profit) each year or $3.27 on an earnings per share basis.

How many employees does Harmony Biosciences have?

The company employs 200 workers across the globe.

How can I contact Harmony Biosciences?

Harmony Biosciences' mailing address is 630 W GERMANTOWN PIKE SUITE 215, PLYMOUTH MEETING PA, 19462. The official website for the company is www.harmonybiosciences.com. The company can be reached via phone at 484-539-9800 or via email at lcaperelli@harmonybiosciences.com.

This page (NASDAQ:HRMY) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -